🇺🇸 FDA
Patent

US 9783595

Neutralizing GP41 antibodies and their use

granted A61KA61K2039/505A61K39/42

Quick answer

US patent 9783595 (Neutralizing GP41 antibodies and their use) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Oct 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Oct 10 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
28
CPC classes
A61K, A61K2039/505, A61K39/42, A61K45/06, A61K49/0004